These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22344231)

  • 1. Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.
    Stein WD; Wilkerson J; Kim ST; Huang X; Motzer RJ; Fojo AT; Bates SE
    Clin Cancer Res; 2012 Apr; 18(8):2374-81. PubMed ID: 22344231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.
    Négrier S; Bushmakin AG; Cappelleri JC; Korytowsky B; Sandin R; Charbonneau C; Michaelson MD; Figlin RA; Motzer RJ
    Eur J Cancer; 2014 Jul; 50(10):1766-1771. PubMed ID: 24768571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
    Harmon CS; DePrimo SE; Figlin RA; Hudes GR; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Williams JA; Eisen T; Motzer RJ
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):151-61. PubMed ID: 24220935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma.
    Blagoev KB; Wilkerson J; Stein WD; Motzer RJ; Bates SE; Fojo AT
    Cell Rep; 2013 Feb; 3(2):277-81. PubMed ID: 23395639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.
    Remák E; Charbonneau C; Négrier S; Kim ST; Motzer RJ
    J Clin Oncol; 2008 Aug; 26(24):3995-4000. PubMed ID: 18711190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
    Cella D; Li JZ; Cappelleri JC; Bushmakin A; Charbonneau C; Kim ST; Chen I; Motzer RJ
    J Clin Oncol; 2008 Aug; 26(22):3763-9. PubMed ID: 18669464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.
    Cella D; Bushmakin AG; Cappelleri JC; Charbonneau C; Michaelson MD; Motzer RJ
    Br J Cancer; 2012 Feb; 106(4):646-50. PubMed ID: 22240794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.
    Dirican A; Kucukzeybek Y; Erten C; Somali I; Demir L; Can A; Payzin KB; Bayoglu IV; Akyol M; Yildiz Y; Koeseoglu M; Alacacioglu A; Tarhan MO
    Asian Pac J Cancer Prev; 2013; 14(3):2101-5. PubMed ID: 23679326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
    Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
    BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α.
    Patil S; Figlin RA; Hutson TE; Michaelson MD; Negrier S; Kim ST; Huang X; Motzer RJ
    Br J Cancer; 2012 May; 106(10):1587-90. PubMed ID: 22568998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population.
    Castellano D; del Muro XG; Pérez-Gracia JL; González-Larriba JL; Abrio MV; Ruiz MA; Pardo A; Guzmán C; Cerezo SD; Grande E
    Ann Oncol; 2009 Nov; 20(11):1803-12. PubMed ID: 19549706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 14. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
    Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
    Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer.
    Heng DY; Chi KN; Murray N; Jin T; Garcia JA; Bukowski RM; Rini BI; Kollmannsberger C
    Cancer; 2009 Feb; 115(4):776-83. PubMed ID: 19127560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
    McKay RR; Lin X; Perkins JJ; Heng DY; Simantov R; Choueiri TK
    Eur Urol; 2014 Sep; 66(3):502-9. PubMed ID: 24613250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
    Scartozzi M; Bianconi M; Faloppi L; Loretelli C; Bittoni A; Del Prete M; Giampieri R; Maccaroni E; Nicoletti S; Burattini L; Minardi D; Muzzonigro G; Montironi R; Cascinu S
    Br J Cancer; 2013 Mar; 108(5):1126-32. PubMed ID: 23511629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
    Adams VR; Leggas M
    Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
    Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL
    J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma.
    Reddy K
    Clin Genitourin Cancer; 2006 Jun; 5(1):23-5. PubMed ID: 16859575
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.